Specifications
Applications
Application Notes
Each laboratory should determine an optimum working titer for use in its particular application.
Other applications have not been tested but use in such assays should not necessarily be excluded.
Images
CABT-L6458Z and DPAB-AV01 bind specifically to AAV9, and the specificity of DPAB-AV01 to AAV9 is slightly better than that of CABT-L6458Z.
Custom Antibody Labeling
We offer labeled antibodies using our catalogue antibody products and a broad range of intensely fluorescent dyes and labels including HRP, biotin, ALP, Alexa Fluor® dyes, DyLight® Fluor dyes, R-phycoerythrin (R-PE), at scales from less than 100 μg up to 1 g of IgG antibody.
Learn More
Citations
Have you cited CABT-L6458Z in a publication?
Let us know and earn a reward for your research.
| Product Name |
Cat. No. |
Applications |
Host Species |
Datasheet |
Price |
Add to Basket |
| Product Name |
Cat. No. |
Applications |
Host Species |
Datasheet |
Price |
Add to Basket |
The Chimeric Mouse Anti-AAV9 monoclonal antibody is derived from a mouse immune system but has been engineered to contain certain regions of human antibody sequences. This chimeric design combines the benefits of mouse antibodies, such as high affinity and specificity, with reduced immunogenicity and improved compatibility with human systems. The antibody recognizes and binds to specific epitopes present on the AAV9 capsid protein, allowing for the detection and quantification of AAV9 particles in various experimental settings. It can be used in techniques such as immunofluorescence microscopy, immunohistochemistry, and flow cytometry to visualize and analyze AAV9 infection and gene transfer efficiency.
One of the main applications of the Chimeric Mouse Anti-AAV9 monoclonal antibody is in the development and optimization of AAV9-based gene therapies. AAV9 has demonstrated remarkable tropism and transduction efficiency in a wide range of tissues, including the central nervous system, heart, liver, skeletal muscle, and lungs. By utilizing the Chimeric Mouse Anti-AAV9 monoclonal antibody, researchers can evaluate the distribution and targeting specificity of AAV9 vectors, assess transduction efficiency in different cell types or organs, and optimize the delivery of therapeutic genes for specific disease treatments. In addition, the Chimeric Mouse Anti-AAV9 monoclonal antibody can contribute to the study of AAV9 biology and the understanding of viral assembly, infection mechanisms, and host immune responses. By characterizing AAV9 particles and their interactions with host cells, researchers can gain insights into the viral life cycle and identify potential targets for antiviral strategies.
Alternative Names
Mouse Anti-AAV9 monoclonal antibody, clone BEL0
Chimeric mouse Anti-AAV9 monoclonal antibody, clone BEL0
Mouse Anti-Adeno-associated virus type 9 monoclonal antibody, clone BEL0
Mouse Anti-Adeno-associated virus 9 monoclonal antibody, clone BEL0
Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible Solutions
Frontiers in Immunology
Authors: Weber T.
Abstract
Adeno-associated virus (AAV) vector-based gene therapy is currently the only in vivo gene therapy approved in the US and Europe. The recent tragic death of three children in a clinical trial to treat X-Linked Myotubular Myopathy by delivering myotubularin with an AAV8 vector notwithstanding, AAV remains a highly promising therapeutic gene delivery platform. But the successful use of AAV vectors to treat an increasing number of diseases also makes establishing protocols to determine therapeutically relevant titers of pre-existing anti-AAV antibodies and approaches to deplete those antibodies more urgent than ever. In this mini review, I will briefly discuss (i) our knowledge regarding the prevalence of anti-AAV antibodies, (ii) the challenges to measure those antibodies by methods that are most predictive of their influence on therapeutic efficacy of AAV gene transfer, and (iii) approaches to overcome the formidable hurdle that anti-AAV antibodies pose to the successful clinical use of AAV gene therapy.
Generation and characterization of anti-AAV8 and anti-AAV9 monoclonal antibodies
Journal of Virological Methods
Authors: Tseng Y S, Van Vliet K, Rao L, et al.
Abstract
Adeno-associated viruses (AAVs) are promising viral vectors for therapeutic gene delivery, and the approval of an AAV1 vector for the treatment of lipoprotein lipase deficiency has heralded a new and exciting era for this system. However, preclinical and clinical studies show that neutralization from pre-existing antibodies is detrimental for medical application and this hurdle must be overcome before full clinical realization can be achieved. Thus the binding sites for capsid antibodies must be identified and eliminated through capsid engineering. Towards this goal and to recapitulate patient polyclonal responses, a panel of eight new mouse monoclonal antibodies (MAbs) has been generated against AAV8 and AAV9 capsids, two vectors in development for therapeutic application. Native (capsid) dot blot assays confirmed the specificity of these antibodies for their parental serotypes, with the exception of one MAb, HL2372, selected to cross-react against both capsids. Furthermore, in vitro assays showed that these MAbs are capable of neutralizing virus infection. These MAbs will be utilized for structural mapping of antigenic footprints on their respective capsids to inform development of the next generation of rAAV vectors capable of evading antibody neutralization while retaining parental tropism.
COA
Certificate of Analysis
